A prospective, randomized, open label, blinded endpoint design to study whether sitagliptin alters the number and proportion of the subsets of circulating CD4+ T Cells in patients with type 2 diabetes.
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.